Cancer Family
Mesenchymal Cell Neoplasm
CI-CAN-00000027Explore in graph →
Non-malignant413 active trials10 approved drugs208 evidence items
- NCIt
- C7059
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000027Explore in graph →
Clinical trials
1,848 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05489237 | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | active not recruiting | Phase 1 | 276 | IDRX, Inc., a wholly owned subsidiary of GSK, LLCINDUSTRY | 11 | Jul 2, 2026 |
| clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06414434 | BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma | active not recruiting | Phase 1 | 24 | Michael Wagner, MDOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04751383 | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | terminated | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 2 | Jun 30, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT07648069 | Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma | recruiting | Phase 1 | 16 | Sun Yat-sen UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07640425 | Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture | recruiting | Phase 1 / Phase 2 | 60 | CONNEXTINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT06235125 | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children(Cytalux) | recruiting | Phase 1 | 10 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06957431 | Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | recruiting | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04796012 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06492954 | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma(AflacST2301) | recruiting | Phase 1 | 12 | Emory UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07144254 | Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma | recruiting | Phase 1 | 24 | Emory UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07171203 | Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor | recruiting | Phase 1 | 18 | University of California, San DiegoOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT03598595 | Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma | active not recruiting | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT06668987 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma | completed | Phase 1 / Phase 2 | 10 | Heron Neutron Medical Corp.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06500819 | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors | recruiting | Phase 1 | 41 | Stanford UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07052383 | Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas | recruiting | Phase 1 | 15 | Tcelltech Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)(PerVision) | recruiting | Phase 1 / Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07357519 | Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) | recruiting | Phase 1 / Phase 2 | 55 | Lantheus Medical ImagingINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT03054792 | Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas | enrolling by invitation | Phase 1 | 18 | The Hospital for Sick ChildrenOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06820164 | Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride | recruiting | Phase 1 / Phase 2 | 20 | West Virginia UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01953900 | iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma(VEGAS) | active not recruiting | Phase 1 | 26 | Baylor College of MedicineOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01590069 | Aerosolized Aldesleukin in Treating Patients With Lung Metastases | active not recruiting | Phase 1 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04308330 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies(NYMC195) | recruiting | Phase 1 | 30 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03594422 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors | recruiting | Phase 1 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03361436 | Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | active not recruiting | Phase 1 | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06566092 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | active not recruiting | Phase 1 | 40 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04833582 | A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma | completed | Phase 1 | 31 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT07096609 | Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients(LONGIST) | recruiting | Phase 1 / Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03721068 | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | recruiting | Phase 1 | 18 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT07479732 | Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | recruiting | Phase 1 / Phase 2 | 56 | Peking University People's HospitalOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04890093 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | suspended | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT02073994 | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | completed | Phase 1 | 174 | Institut de Recherches Internationales ServierOTHER | 2 | Feb 17, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 6, 2026source: clinicaltrials